PL3655553T3 - Sposoby wykrywania dyskrazji komórek plazmatycznych - Google Patents

Sposoby wykrywania dyskrazji komórek plazmatycznych

Info

Publication number
PL3655553T3
PL3655553T3 PL18755985.1T PL18755985T PL3655553T3 PL 3655553 T3 PL3655553 T3 PL 3655553T3 PL 18755985 T PL18755985 T PL 18755985T PL 3655553 T3 PL3655553 T3 PL 3655553T3
Authority
PL
Poland
Prior art keywords
methods
plasma cell
cell dyscrasias
detecting plasma
detecting
Prior art date
Application number
PL18755985.1T
Other languages
English (en)
Polish (pl)
Inventor
Irvin Mark MODLIN
Mark Kidd
Ignat Drozdov
Original Assignee
Liquid Biopsy Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Research LLC filed Critical Liquid Biopsy Research LLC
Publication of PL3655553T3 publication Critical patent/PL3655553T3/pl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6818Sequencing of polypeptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL18755985.1T 2017-07-21 2018-07-18 Sposoby wykrywania dyskrazji komórek plazmatycznych PL3655553T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762535419P 2017-07-21 2017-07-21
PCT/US2018/042712 WO2019018540A1 (en) 2017-07-21 2018-07-18 METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA

Publications (1)

Publication Number Publication Date
PL3655553T3 true PL3655553T3 (pl) 2022-09-26

Family

ID=63244986

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18755985.1T PL3655553T3 (pl) 2017-07-21 2018-07-18 Sposoby wykrywania dyskrazji komórek plazmatycznych

Country Status (13)

Country Link
US (2) US20190025311A1 (https=)
EP (1) EP3655553B1 (https=)
JP (1) JP7223741B2 (https=)
KR (1) KR102785072B1 (https=)
CN (1) CN111194356B (https=)
AU (1) AU2018304242B2 (https=)
BR (1) BR112020000791A2 (https=)
DK (1) DK3655553T3 (https=)
ES (1) ES2916450T3 (https=)
IL (1) IL271465B2 (https=)
MX (1) MX2020000785A (https=)
PL (1) PL3655553T3 (https=)
WO (1) WO2019018540A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3655553B1 (en) 2017-07-21 2022-03-23 Liquid Biopsy Research LLC Methods for detection of plasma cell dyscrasia
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.
CN111349705A (zh) * 2020-03-18 2020-06-30 昆明医科大学 circASXL1作为肺癌诊断标志物及其运用
CA3180572A1 (en) * 2020-05-29 2021-12-02 Johan Skog Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512557A (ja) * 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
JP2004313167A (ja) * 2003-02-24 2004-11-11 Joji Inasawa 薬剤耐性マーカーおよびその利用
DK2537942T3 (en) * 2004-05-21 2015-12-14 Trustees Of The University Of Arkansas System Board Of Use of genudtryksprofilering to predict survival in cancer patients
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
JP2012514460A (ja) * 2009-01-02 2012-06-28 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー ボルテゾミブを用いた多発性骨髄腫患者における生存率の予測
WO2011152884A2 (en) 2010-06-04 2011-12-08 Board Of Trustees Of The University Of Arkansas 14 gene signature distinguishes between multiple myeloma subtypes
WO2013155048A1 (en) 2012-04-10 2013-10-17 University Of Utah Research Foundation Compositions and methods for diagnosing and classifying multiple myeloma
EP3655553B1 (en) 2017-07-21 2022-03-23 Liquid Biopsy Research LLC Methods for detection of plasma cell dyscrasia

Also Published As

Publication number Publication date
JP2020528274A (ja) 2020-09-24
AU2018304242A1 (en) 2020-01-16
US12366575B2 (en) 2025-07-22
US20190025311A1 (en) 2019-01-24
DK3655553T3 (da) 2022-06-20
BR112020000791A2 (pt) 2020-07-21
KR20200029528A (ko) 2020-03-18
US20230022417A1 (en) 2023-01-26
WO2019018540A1 (en) 2019-01-24
EP3655553B1 (en) 2022-03-23
CN111194356B (zh) 2024-04-23
EP3655553A1 (en) 2020-05-27
CA3067730A1 (en) 2019-01-24
KR102785072B1 (ko) 2025-03-20
ES2916450T3 (es) 2022-07-01
IL271465A (en) 2020-01-30
IL271465B1 (en) 2023-04-01
IL271465B2 (en) 2023-08-01
CN111194356A (zh) 2020-05-22
MX2020000785A (es) 2020-11-06
AU2018304242B2 (en) 2023-04-27
JP7223741B2 (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
ZA201708231B (en) Detection of chromosome interactions
EP3459022A4 (en) Predictive drift detection and correction
KR20180084820A (ko) 전기화학적 기체 분리 방법
DK3465098T3 (da) Detektering af objekter
EP3408402A4 (en) MAGNETIC ELECTROCHEMICAL DETECTION
DK3134553T3 (da) Kolorimetrisk detektering af nukleinsyreamplifikation
EP3191599C0 (en) DETECTION OF MISFOLDED PROTEINS
DK3227435T3 (da) Gammadelta-t-celleekspansionsprocedure
DK3212802T3 (da) Fremgangsmåde til detektering af kontamination med hussvamp
EP3693453C0 (en) CELL CAPTURE DEVICE
DK3183362T3 (da) Elektrokemisk detektering af mikroorganismer
HUE042606T2 (hu) Eljárás apolipoprotein kimutatására
PL3365685T3 (pl) Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
PL3384045T3 (pl) Sposób określania klonalności komórek
PL3239588T3 (pl) Sposób wykrywania substancji
IL275288B1 (en) Methods for obtaining muscle derived cells
FR3014237B1 (fr) Procede de detection de la voix
PL3655553T3 (pl) Sposoby wykrywania dyskrazji komórek plazmatycznych
PL3589742T3 (pl) Sposób wykrywania
EP3552007A4 (en) GAS DETECTION TECHNIQUE
DK3289363T3 (da) Specifik påvisning af clusterin isoformer
DK3748358T3 (da) Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid
BR112017007401A2 (pt) métodos de detecção específicos
SG11201610430QA (en) Growth-independent detection of cells
EP3287522A4 (en) DETECTION OF FGFR2